Responses Seen With Anti-PD-1 Antibody in Anaplastic Thyroid Cancer Cohort
Lori J. Wirth, MD, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.
Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.
Overall, 42 patients were enrolled and received spartalizumab (PDR001). Besides dabrafenib (Tafinlar) and trametinib (Mekinist), this patient population has very limited treatment options. However, Wirth reported that these patients had a 22% response rate with spartalizumab.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
